Pharmaceuticals, Gregis (Bayer): "Scientific Research Down 10 Points in 10 Years"
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.7 Articles
7 Articles
Il Tempo
Cernobbio, 7 Sep. (Adnkronos Salute) - "Europe runs the risk of being considered only a market and not being a protagonist. This is avoidable. If we look at European excellence in science, they are extraordinary: we have clinical research of first level, human capital, university, productive capacity. The problem is how to translate this scientific excellence into a rapid impact in people's lives. The data speak out if we look at scientific rese…
In an increasingly complex global scenario, Europe is called to defend its strategic role in the high-innovation sectors, starting with Life Science. Between geopolitical tensions, energy costs and increasing international competition, the challenge is to transform scientific excellence into investments, research and production capacity. At the Teha Group Forum in Cernobbio, Arianna Gregis, CEO of Bayer Italia, analyzes the conditions necessary …
(Adnkronos) "Europe runs the risk of being considered only a market and not being a protagonist. This is avoidable. If we look at European excellence in science, they are extraordinary: we have clinical research of first level, human capital, university, productive capacity. The problem is how to translate this scientific excellence into a rapid impact in life [...]
notizie.it
Rec News | Lontani dal mainstream(Adnkronos) - "Europe runs the risk of being considered only a market and not being a protagonist. This is avoidable. If we look at the excellences
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
